• DOI:10.3389/fphar.2016.00197
Corpus ID: 16375680

Introduction and Utilization of High Priced HCV Medicines across Europe; Implications for the Future

@article{Bruijn2016IntroductionAU,
  title={Introduction and Utilization of High Priced HCV Medicines across Europe; Implications for the Future},
  author={Winnie de Bruijn and Cristina Ib{\'a}{\~n}ez and P. Frisk and Hanne Bak Pedersen and A. Alkan and Patricia Vella Bonanno and L. S. Brki{\vc}i{\'c} and A. Bucsics and Guillaume Dedet and J. Eriksen and Joseph Fadare and Jurij F{\"u}rst and G. Gallego and I. P. God{\'o}i and A. G. Guerra J{\'u}nior and Hakkı G{\"u}rs{\"o}z and S. Jan and J. Jones and R. Joppi and S. Kerman and O. Laius and Newman Madzikwa and Einar Magn{\'u}sson and M. Maticic and Vanda Markovi{\'c}-Pekovi{\'c} and A. Massele and O. Ogunleye and A. O'Leary and Jutta Piessnegger and C. Sermet and S. Simoens and C. Tiroyakgosi and I. Truter and Magnus Thyberg and K. Tomekova and M. Władysiuk and Sotiris Vandoros and E. H. Vural and Corinne Zara and B. Godman},
  journal={Frontiers in Pharmacology},
  year={2016},
  volume={7}
}

• Winnie de Bruijn, Cristina Ibáñez, +37 authors B. Godman
• Published 2016
• Medicine
• Frontiers in Pharmacology

Background: Infection with the Hepatitis C Virus (HCV) is a widespread transmittable disease with a diagnosed prevalence of 2.0%. Fortunately, it is now curable in most patients. Sales of medicines to treat HCV infection grew 2.7% per year between 2004 and 2011, enhanced by the launch of the protease inhibitors (PIs) boceprevir (BCV) and telaprevir (TVR) in addition to ribavirin and pegylated interferon (pegIFN). Costs will continue to rise with new treatments including sofosbuvir, which now… Expand

View on PubMed

frontiersin.org

Save to Library

Create Alert

Cite

Launch Research Feed